Search Results - Edith A. Perez

Edith A. Perez

Edith A. Perez, M.D., is an internationally renowned hematologist-oncologist and thought leader committed to advancing cancer drug development and improving patient care through health equity and access to innovative treatments. Perez is a highly respected leader and role model for future generations, with over 700 peer-reviewed authored or co-authored manuscripts and abstracts, reflected by her frequent invitations to lecture at national and international meetings as well as serving on the board of multiple academic journals and holding leadership and advisory positions across academic, clinical, and industry settings, including Professor Emeritus at [https://www.mayoclinic.org/ Mayo Clinic]. Provided by Wikipedia
  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    720 A phase 1/2 study of BDC-3042, a novel Dectin-2 agonistic antibody, in patients with advanced cancers by Edith A Perez, Lu Xu, Antonio Giordano, Justin Kenkel, Shelley E Ackerman, Michael N Alonso, Sharon Wilks, Aparna R Parikh, Danlin Cai, Damon Demady

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  2. 2

    Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study by Edith A Perez, Elizabeth M Jaffee, John Whyte, Cheryl A Boyce, John D Carpten, Guillermina Lozano, Raymond M Williams, Karen M Winkfield, David Bernstein, Sung Poblete

    Published in JMIR Cancer (2021-09-01)
    Get full text
    Article


  3. 3

    Impact of library preparation on downstream analysis and interpretation of RNA-Seq data: comparison between Illumina PolyA and NuGEN Ovation protocol. by Zhifu Sun, Yan W Asmann, Asha Nair, Yuji Zhang, Liguo Wang, Krishna R Kalari, Aditya V Bhagwate, Tiffany R Baker, Jennifer M Carr, Jean-Pierre A Kocher, Edith A Perez, E Aubrey Thompson

    Published in PLoS ONE (2013-01-01)
    Get full text
    Article


  4. 4

    821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab by Edith A Perez, Andrew Luo, Anthony Lucas, Han K Kim, Paul D Ponath, Katelynn A McEachin, Karla A Henning, Shelley E Ackerman, Steven J Chapin, Michael N Alonso, Cecelia I Pearson, David Omstead

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  5. 5

    Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials by Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson

    Published in npj Breast Cancer (2022-05-01)
    Get full text
    Article


  6. 6

    716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or ga... by Jean-Yves Blay, Antoine Italiano, Stephane Champiat, Paolo Antonio Ascierto, Manish Sharma, Jeeyun Lee, Luis Paz-Ares Rodriguez, Keun-Wook Lee, Yoon-Koo Kang, Drew Rasco, Edith A Perez, Mariano Ponz-Sarvise, Lu Xu, Jean-Philippe Spano, Coya Tapia, Ecaterina Dumbrava, Kathleen Moore, Jason Ptacek, Michele Magni, Alfonso Cortes Salgado, Ming Yin, Agnese Losurdo, Antoine Deleuze, Mark D Pegram, Ardaman Shergill, Alexander I Spira, Michael N Alonso, Joan Albanell Mestres, Marta GilMartin, Arielle Heeke, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Bob T Li

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  7. 7

    The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group by Khalid El Bairi, Harry R. Haynes, Elizabeth Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Masoumeh Gharib, Amine Kallala, Indu Arun, Farid Azmoudeh-Ardalan, Luciana Fujimoto, Luz F. Sua, Shi-Wei Liu, Huang-Chun Lien, Pawan Kirtani, Marcelo Balancin, Hicham El Attar, Prerna Guleria, Wenxian Yang, Emad Shash, I-Chun Chen, Veronica Bautista, Jose Fernando Do Prado Moura, Bernardo L. Rapoport, Carlos Castaneda, Eunice Spengler, Gabriela Acosta-Haab, Isabel Frahm, Joselyn Sanchez, Miluska Castillo, Najat Bouchmaa, Reena R. Md Zin, Ruohong Shui, Timothy Onyuma, Wentao Yang, Zaheed Husain, Karen Willard-Gallo, An Coosemans, Edith A. Perez, Elena Provenzano, Paula Gonzalez Ericsson, Eduardo Richardet, Ravi Mehrotra, Sandra Sarancone, Anna Ehinger, David L. Rimm, John M. S. Bartlett, Giuseppe Viale, Carsten Denkert, Akira I. Hida, Christos Sotiriou, Sibylle Loibl, Stephen M. Hewitt, Sunil Badve, William Fraser Symmans, Rim S. Kim, Giancarlo Pruneri, Shom Goel, Prudence A. Francis, Gloria Inurrigarro, Rin Yamaguchi, Hernan Garcia-Rivello, Hugo Horlings, Said Afqir, Roberto Salgado, Sylvia Adams, Marleen Kok, Maria Vittoria Dieci, Stefan Michiels, Sandra Demaria, Sherene Loi, The International Immuno-Oncology Biomarker Working Group

    Published in npj Breast Cancer (2021-12-01)
    Get full text
    Article


Search Tools: